Jazz’s $1 Billion Buyout Of Gentium Adds To European Hematology Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
The $1 billion purchase price is tied to EU-approved Defitelio, an orphan drug to treat a rare hepatic disorder in patients receiving stem-cell transplants. The drug is not approved in the U.S. – an NDA was pulled in 2011 due to FDA concerns about data quality.
You may also be interested in...
Jazz Tunes Up For Business Development
With a highly competitive effective tax rate, half a billion dollars in cash, and access to attractively priced capital, specialty pharma Jazz, itself the subject of takeover rumors, has stepped up its ongoing hunt for late-stage assets.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.